PT853477E - Antagonistas de receptores at1 para prevencao e tratamento de insuficiencia renal pos-isquemica e para proteccao de rim isquemico - Google Patents

Antagonistas de receptores at1 para prevencao e tratamento de insuficiencia renal pos-isquemica e para proteccao de rim isquemico

Info

Publication number
PT853477E
PT853477E PT96933369T PT96933369T PT853477E PT 853477 E PT853477 E PT 853477E PT 96933369 T PT96933369 T PT 96933369T PT 96933369 T PT96933369 T PT 96933369T PT 853477 E PT853477 E PT 853477E
Authority
PT
Portugal
Prior art keywords
ischemic
iskemic
pos
prevention
treatment
Prior art date
Application number
PT96933369T
Other languages
English (en)
Inventor
Ulrich Humke
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4242452&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT853477(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT853477E publication Critical patent/PT853477E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
PT96933369T 1995-10-06 1996-09-24 Antagonistas de receptores at1 para prevencao e tratamento de insuficiencia renal pos-isquemica e para proteccao de rim isquemico PT853477E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH282595 1995-10-06

Publications (1)

Publication Number Publication Date
PT853477E true PT853477E (pt) 2003-01-31

Family

ID=4242452

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96933369T PT853477E (pt) 1995-10-06 1996-09-24 Antagonistas de receptores at1 para prevencao e tratamento de insuficiencia renal pos-isquemica e para proteccao de rim isquemico

Country Status (16)

Country Link
US (1) US6071931A (pt)
EP (1) EP0853477B1 (pt)
JP (3) JPH11513395A (pt)
AT (1) ATE225657T1 (pt)
AU (1) AU7213296A (pt)
BR (1) BR9611007A (pt)
CA (1) CA2232663C (pt)
CY (1) CY2428B1 (pt)
DE (1) DE69624253T2 (pt)
DK (1) DK0853477T3 (pt)
ES (1) ES2184892T3 (pt)
MY (1) MY119312A (pt)
PT (1) PT853477E (pt)
TW (1) TW445147B (pt)
WO (1) WO1997013513A1 (pt)
ZA (1) ZA968378B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0855392A3 (de) * 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
IT1295405B1 (it) 1997-09-30 1999-05-12 Merck Sharp & Dohme Italia S P Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di
HUP0003982A3 (en) 1997-10-17 2002-01-28 Eurogene Ltd The use of inhibitors of the renin-angiotensin system for producing pharmaceutical compositions using for the treatment of hypoxia or impaired metabolic function
AU3043000A (en) 1998-12-23 2000-07-31 Novartis Ag Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
SE9902597D0 (sv) 1999-07-06 1999-07-06 Astra Ab New use
AU2001285768B2 (en) * 2000-06-22 2005-03-10 Novartis Ag Solid valsartan pharmaceutical compositions
AR032758A1 (es) * 2000-07-19 2003-11-26 Novartis Ag Sales valsartan, un proceso para su fabricacion, composiciones farmaceuticas y el uso de dichas sales para la preparacion de medicamentos
US20030187038A1 (en) * 2000-08-25 2003-10-02 Yoshimi Imura Fibrinogen-lowering agents
AU2003223637A1 (en) * 2002-04-15 2003-11-03 Dr. Reddy's Laboratories Limited Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan)
WO2005097109A1 (en) * 2004-04-01 2005-10-20 Daniel Batlle Methods for achieving a protective ace2 expression level
US10716749B2 (en) * 2005-11-03 2020-07-21 Palo Alto Investors Methods and compositions for treating a renal disease condition in a subject
JP2011063518A (ja) * 2009-09-15 2011-03-31 Tohoku Univ Ａｒｂ及び／又はグリタゾン系血糖降下物質を含有するｏａｔｐ−ｒ遺伝子発現増強組成物
RU2456615C1 (ru) * 2011-03-25 2012-07-20 Федеральное государственное учреждение "Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения и социального развития Российской Федерации Способ профилактики отторжения трансплантата трупной почки
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
DE69034103T2 (de) * 1989-06-14 2004-07-15 Smithkline Beecham Corp. Imidazoalkensäure
IE70593B1 (en) * 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
ATE134624T1 (de) * 1990-02-19 1996-03-15 Ciba Geigy Ag Acylverbindungen
NZ237476A (en) * 1990-03-20 1994-01-26 Sanofi Sa N-substituted heterocyclic compounds and pharmaceutical compositions.
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IL99246A0 (en) * 1990-09-10 1992-07-15 Abbott Lab Angiotensin ii receptor antagonists and pharmaceutical compositions containing them
SI9210098B (sl) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5196537A (en) * 1991-03-21 1993-03-23 G. D. Searle & Co. 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
GB9110636D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
EP0872235A1 (en) * 1992-04-13 1998-10-21 Zeneca Limited Therapeutic agents
EP0720477A1 (en) * 1992-09-09 1996-07-10 Vanderbilt University Method and compositions for maintaining glomerular filtration rate while inhibition extracellular matrix accumulation
EP0629408A1 (en) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Combination of angiotensin converting enzyme inhibitors and AII antagonists

Also Published As

Publication number Publication date
ZA968378B (en) 1997-04-07
JP2008019273A (ja) 2008-01-31
CA2232663A1 (en) 1997-04-17
EP0853477A1 (en) 1998-07-22
WO1997013513A1 (en) 1997-04-17
AU7213296A (en) 1997-04-30
JP2011256195A (ja) 2011-12-22
DE69624253T2 (de) 2003-08-07
ES2184892T3 (es) 2003-04-16
JPH11513395A (ja) 1999-11-16
CY2428B1 (en) 2004-11-12
CA2232663C (en) 2008-04-08
BR9611007A (pt) 1999-07-13
EP0853477B1 (en) 2002-10-09
ATE225657T1 (de) 2002-10-15
US6071931A (en) 2000-06-06
DK0853477T3 (da) 2003-02-10
MY119312A (en) 2005-05-31
TW445147B (en) 2001-07-11
DE69624253D1 (de) 2002-11-14

Similar Documents

Publication Publication Date Title
PT853477E (pt) Antagonistas de receptores at1 para prevencao e tratamento de insuficiencia renal pos-isquemica e para proteccao de rim isquemico
ES2552639T3 (es) Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos
CY2567B1 (en) Treatment of normotensive glaucoma with angiotensin II antagonists
LU93229I2 (fr) "pitolisant et ses sels pharmaceutiquement acceptables, tel que chlorhydrate"
EP0826671A4 (en) HETEROCYCLIC AMIDE DERIVATIVES AND THEIR MEDICAL USE
WO2001076573A3 (en) Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups
ATE196295T1 (de) Corticotropinfreisetzungsfaktor antagonisten
NO971470L (no) Nye pyrimidon-derivater med fungicid aktivitet
ES2185660T3 (es) Nuevo uso de dexmedetomidina.
CY1105257T1 (el) Χρηση των ανταγωνιστων των υποδοχεων της αγγειοτενσινης ii στην θepαπεια του οξεος εμφραγματος του μυοκαρδιου
ES2105286T3 (es) Derivados de etanolamina que tienen actividades simpatomimetica y anti-polaquiuria.
NO981856D0 (no) Anvendelse av 1-(2-naft-2-yletyl)-4-(3-trifluormetylfenyl)-1,2,3,6-tetrahydropyridin for fremstilling av legemidler for behandling av amyotrof lateral sclerose
NO974400L (no) Kombinasjonspreparater inneholdende benazepril eller benazeprilat og valsartan
CA2427814A1 (en) A combination of a pde4 inhibitor and a leukotriene antagonist in the treatment of bronchial and respiratory disorders
DE69415341D1 (de) Kondensierte tricyclische heteroaromatische derivate als liganden des dopamin-rezeptor-subtyps
DE69407191T2 (de) Kondensierte tricyclische heteroaromatische verbindungen als dopamin-rezeptor-subtyp-liganden
CA2432177A1 (en) Drug for prevention and/or therapy of endometriosis
TW200518747A (en) Additional pharmaceutical use
WO2001072669A3 (en) Therapeutic use of polyhydroxy amine derivates
GR3027644T3 (en) Therapeutic compositions containing a lithium compound and silica
NO963869L (no) Behandling av diabetisk nefropati med valsartan